Entity

Time filter

Source Type

Quebec, Canada

Æterna Zentaris Inc. is a Quebec, Canada-based biopharmaceutical drug development company focused in oncology and endocrine therapy, currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It has over 80 employees in Canada, USA and Germany. The company is based in Canada, the development and research site is based in Germany. The company has 3 lead projects: an ongoing Phase 3 trial in multiple myeloma conducted under a Special Protocol Assessment : a Phase 3 trial in endometrial cancer with AEZS-108 expected to be initiated in 1Q 2013, and a New Drug Application expected to be filed in 1Q 2013 for the approval of AEZS-130 as potentially the first oral diagnostic test for adult growth hormone deficiency .Perifosine: Fast track designation and orphan drug status granted by the FDA. Orphan Medicinal Product designation and positive Scientific Advice granted by the EMA .AEZS-108: Orphan drug and Orphan medicinal product designations granted by the FDA and EMA respectively, for the treatment of ovarian cancer.AEZS-130: Orphan drug designation granted by the FDA for use as a diagnostic test for AGHD. Wikipedia.


The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors.


LHRH analogues and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and/or advanced prostate carcinoma, by administering an initial dose of an LHRH analogue over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an LHRH antagonist over a second period, the dose being insufficient to achieve and/or maintain hormonal castration.


Patent
AEterna Zentaris | Date: 2012-04-04

The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.


The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.


The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.

Discover hidden collaborations